Scarica l'app Stockscreener
8.28
0.18%
0.015
Dopo l'orario di chiusura:
8.28
Precedente Chiudi:
$8.265
Aprire:
$8.28
Volume 24 ore:
985.61K
Relative Volume:
0.70
Capitalizzazione di mercato:
$2.59B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-12.17
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
-4.39%
1M Prestazione:
-1.19%
6M Prestazione:
+1.10%
1 anno Prestazione:
+36.63%
Intervallo 1D:
$8.195
$8.40
Intervallo di 1 settimana:
$8.18
$8.9499
Portata 52W:
$5.18
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
8.28 | 2.59B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
ZTS
Zoetis Inc
|
163.11 | 73.07B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.05 | 47.43B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.24 | 45.72B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.08 | 17.28B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.81 | 14.03B | 612.78M | -86.37M | -62.91M | -0.87 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Myasthenia Gravis Treatment Market Size, Growth Analysis 2031 - openPR
Insiders At Amneal Pharmaceuticals Sold US$48m In Stock, Alluding To Potential Weakness - Simply Wall St
Amneal Digs Deeper Into GLP-1 Aspirations Following Metsera’s IPO - Citeline
Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued (NASDAQ:AMRX) - Seeking Alpha
Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment - Markets Insider
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals’ SWOT analysis: generic drug maker’s stock poised for growth - Investing.com
Amneal at Barclays Healthcare Conference: Growth and Innovation Insights By Investing.com - Investing.com UK
Amneal to Participate at Upcoming March 2025 Investor Conference - BioSpace
Amneal to Participate at Upcoming Investor Conference - WICZ
Amneal Pharmaceuticals CEO Set for Key Presentation at Barclays Healthcare Conference - StockTitan
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock By Investing.com - Investing.com Australia
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock By Investing.com - Investing.com Australia
Insider Exodus: Amneal Pharmaceuticals Executives and Directors Offload Massive Stock Holdings - TipRanks
Amneal Pharmaceuticals EVP Jason Daly sells $792,159 in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock By Investing.com - Investing.com Canada
Teva denied stay in Amneal patent dispute as it appeals to Supreme Court - MLex
Amneal Pharmaceuticals EVP Andrew Boyer sells $1.1 million in stock - Investing.com
Amneal Pharmaceuticals CFO Tasos Konidaris sells $891,000 in stock - Investing.com
Amneal Pharmaceuticals director Alva Emily Peterson sells $712,000 in stock - Investing.com
Amneal Pharmaceuticals Executives and Director Sell Shares - TradingView
Polycystic Ovarian Syndrome Treatment Market Set for USD 4.3 Billion by 2034 as Demand for Personalized Medicine Rises | Exclusive Report by TMR - GlobeNewswire Inc.
Amneal’s Rytary Follow-On Crexont Could Hit $500m In Sales - Insights
Principal Financial Group Inc. Purchases 8,213 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals director Patel sells $712,000 in stock By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals director Patel sells $712,000 in stock - Investing.com India
Amneal Receives FDA Approval for Lenalidomide - Clinical Oncology News
Amneal Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - The Globe and Mail
US Denosumab Race Remains Busy As Amneal And mAbxience See Filing Accepted - Citeline
Handelsbanken Fonder AB Acquires Shares of 39,000 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Rhumbline Advisers Purchases 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal Pharmaceuticals (NASDAQ:AMRX) Given New $11.00 Price Target at Barclays - Defense World
Amneal’s BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - BioSpace
Full Fed. Circ. Won't Take On Teva's Orange Book Appeal - Law360
Amneal projects $3B-$3.1B revenue in 2025 with biosimilars and CREXONT as key drivers - MSN
Amneal, mAbxience's Biologics Licensing Application for Denosumab Biosimilars Accepted for Review by FDA - Marketscreener.com
Amneal seeks FDA nod for bone therapy biosimilars By Investing.com - Investing.com South Africa
Amneal seeks FDA nod for bone therapy biosimilars - Investing.com
Amneal Pharmaceuticals BLA submissions for denosumab biosimilars accepted by FDA - TipRanks
Amneal's BLA Submissions for Two Denosumab Biosimilars Accepted for Review by U.S. FDA - Marketscreener.com
New York State Common Retirement Fund Boosts Stock Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $10.60 - Defense World
JP Morgan Upgrades Amneal Pharmaceuticals (AMRX) - MSN
Amneal Pharmaceuticals’ Earnings Call Highlights Robust Growth - MSN
Is Amneal Pharmaceuticals, Inc. (AMRX) the Best Weight Loss Drug Stock to Buy According to Analysts? - Insider Monkey
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.70%
0.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):